Pulmonary Arterial Hypertension Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's, "Pulmonary Arterial Hypertension Pipeline Insight 2025" report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the Pulmonary Arterial Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Pulmonary Arterial Hypertension Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Arterial Hypertension Pipeline Outlook [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report

* On September 3, 2025, the International University of Health and Welfare initiated a study to evaluate the efficacy of satralizumab in patients with pulmonary arterial hypertension (PAH) characterized by an immune-responsive phenotype, defined as serum interleukin-6 (IL-6) levels greater than or equal to 2.73 pg/mL, who have demonstrated an inadequate response to existing therapies.
* DelveInsight's Pulmonary Arterial Hypertension Pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Pulmonary Arterial Hypertension treatment.
* The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
* Promising Pulmonary Arterial Hypertension Pipeline Therapies such as TPN171H, Tadalafil, Bosentan, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept, Macitentan, Treprostinil Palmitil and others.

Get insights into Pulmonary Arterial Hypertension Clinical Trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Arterial Hypertension Treatment Drugs [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pulmonary Arterial Hypertension Emerging Drugs Profile

* Sotatercept: Acceleron Pharma

Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF- superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.

* LIQ861: Liquidia Technologies

LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company's novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH). The Pulmonary Arterial Hypertension Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
* Pulmonary Arterial Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market

Explore groundbreaking therapies and clinical trials in the Pulmonary Arterial Hypertension Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Arterial Hypertension Drugs [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pulmonary Arterial Hypertension Companies

Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.

Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravitreal
* Subretinal
* Topical
* Molecule Type

Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Learn about new Pulmonary Arterial Hypertension drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Arterial Hypertension Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Pulmonary Arterial Hypertension Pipeline Report

* Coverage- Global
* Pulmonary Arterial Hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
* Pulmonary Arterial Hypertension Pipeline Therapies- TPN171H, Tadalafil, Bosentan, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept, Macitentan, Treprostinil Palmitil and others.
* Pulmonary Arterial Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pulmonary Arterial Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth Pulmonary Arterial Hypertension Pipeline report today! @ Pulmonary Arterial Hypertension Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Pulmonary Arterial Hypertension: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pulmonary Arterial Hypertension - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Sotatercept: Acceleron Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* GB-002: Gossamer Bio
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Apabetalone: Resverlogix
* Drug profiles in the detailed report.....
* Preclinical/Discovery Stage Products
* R107: Radikal Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Pulmonary Arterial Hypertension Key Companies
* Pulmonary Arterial Hypertension Key Products
* Pulmonary Arterial Hypertension- Unmet Needs
* Pulmonary Arterial Hypertension- Market Drivers and Barriers
* Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
* Pulmonary Arterial Hypertension Analyst Views
* 26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-arterial-hypertension-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.